Focus: Drug candidates derailed in case of mistaken identity

PARP inhibitor that wasn’t highlights widespread flaws in preclinical studies.

DRUG	STAGE	CANCER
Olaparib (AZD-2281)	Phase I	Solid tumors
Veliparib (ABT-888)	Phase I, II	Prostate, colorectal, leukemias, solid tumors
CEP-9722	Phase I, II	Solid tumors, lymphoma
Rucaparib (CO-338)	Phase I, II	BRCA1/2 mutant cancers, solid tumors
E7016	Phase I	Solid tumors
BMN-673	Phase I	Leukemias, solid tumors

Table: Despite flagging enthusiasm, several PARP-inhibitor drugs are still making their way through clinical trials.

Source: ClinicalTrials.gov, data accessed 29 March 2012.

Source: Drug candidates derailed in case of mistaken identity. Heidi Ledford. Nature 29 March 2012, volume 483, 519.

Free paper available at: http://www.nature.com/polopoly_fs/1.10341!/import/pdf/483519a.pdf